RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Sound waves may boost immunotherapy in head and neck cancer
Disease control Recruiting nowThis early-stage trial tests whether using ultrasound and microbubbles can help deliver the immunotherapy drug pembrolizumab more effectively to tumors in people with recurrent or metastatic head and neck cancer. Six participants will receive three rounds of treatment. The main g…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 10:00 UTC
-
Triple therapy aims to reignite immune attack on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests whether combining three treatments—modified natural killer cells (PD-L1 t-haNK), an immune-boosting protein (Anktiva), and a targeted antibody (cetuximab)—can shrink tumors in people with advanced head and neck cancer that has come back or spread. About 25 adults…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy targets HPV-driven head and neck cancer in major trial
Disease control Recruiting nowThis study tests whether adding an experimental vaccine (BNT113) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced head and neck cancer caused by HPV. About 350 adults with incurable, recurrent, or metastatic cancer tha…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated May 20, 2026 11:57 UTC